Phase I/II Study of Combination Therapy of Antibody Hu3F8 With Granulocyte- Macrophage Colony Stimulating Factor (GM-CSF) in Patients With Relapsed/Refractory High-Risk Neuroblastoma

Trial Profile

Phase I/II Study of Combination Therapy of Antibody Hu3F8 With Granulocyte- Macrophage Colony Stimulating Factor (GM-CSF) in Patients With Relapsed/Refractory High-Risk Neuroblastoma

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 10 Feb 2017

At a glance

  • Drugs Monoclonal antibody 3F8 (Primary) ; Granulocyte macrophage colony stimulating factor
  • Indications Neuroblastoma
  • Focus Adverse reactions
  • Most Recent Events

    • 17 May 2016 Study phase changed from I to I/II (addition of an expansion phase); Treatment for phase II (expansion phase) added and patient number changed.
    • 17 May 2016 Planned number of patients changed from 102 to 224.
    • 17 May 2016 Planned End Date changed from 1 Dec 2017 to 1 Dec 2021.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top